RESUMO
Advanced glycation end products (AGEs) are a contributing factor in the angiogenesis that is characteristic of proliferative diabetic retinopathy. However, a previous study made a promising observation that domain IIV of ß2glycoprotein I (DIIV) inhibits angiogenesis in human umbilical vein cells. The present study aimed to confirm the inhibition of AGEinduced angiogenesis in retinal endothelial cells by DIIV and to investigate the potential underlying mechanisms. The RF/6A rhesus macaque choroidretinal vascular endothelial cell line was cultured in vitro and treated with AGEs in the presence or absence of different concentrations of DIIV. The proliferation, migration and tube formation of the RF/6A cells were evaluated using MTS assays, in vitro wound healing assays and in vitro Matrigel angiogenesis assays, respectively. The mRNA expression of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR) 2, VEGFR 1 and receptor for AGE (RAGE) were quantified by reverse transcription quantitative polymerase chain reaction. The expression of VEGFR1, VEGFR2 and the activation of protein kinase B (Akt) and extracellular signalregulated kinase (ERK) were also assessed by western blot analysis. The results indicated that AGEs promoted the migration, proliferation and tube formation of RF/6A cells in vitro (P<0.05), increased the expression of VEGF, VEGFR2 and RAGE (P<0.05) and increased the phosphorylation of Akt and ERK (P<0.05). DIIV inhibited the increase in VEGFR2 mRNA and protein, but did not inhibit the increase in VEGF or RAGE mRNAs. These results led to the conclusion that DIIV inhibited AGEinduced angiogenesis in the RF/6A cells, which was accompanied by a downregulation in the expression of VEGFR2 and its downstream phosphatidylinosol 3kinase/Akt and mitogenactivated protein kinase/ERK1/2 pathways. These findings provide further support towards the treatment of proliferative diabetic retinopathy by interventions that act via a mechanism similar to that of DIIV.
Assuntos
Produtos Finais de Glicação Avançada/farmacologia , Neovascularização Fisiológica/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo , beta 2-Glicoproteína I/farmacologia , Animais , Linhagem Celular , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Expressão Gênica , Humanos , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno/metabolismo , Fosforilação , Domínios e Motivos de Interação entre Proteínas , Proteínas Proto-Oncogênicas c-akt/metabolismo , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/genética , beta 2-Glicoproteína I/químicaRESUMO
ß2glycoprotein I (ß2GPI), also known as apolipoprotein H, is a phospholipidbinding plasma protein consisting of five homologous repeated units. ß2GPI downregulates vascular endothelial growth factor (VEGF) signaling pathways and inhibits angiogenesis in vitro. However, the in vivo roles and effectors of reduced ß2GPI and ß2GPI in retinal angiogenesis are still not fully understood. In this study, an oxygeninduced retinopathy model was used to investigate the effects of reduced ß2GPI and ß2GPI, and to monitor the expression of VEGF, VEGF receptor (VEGFR) 1, VEGFR2 and hypoxiainducible factor 1 (HIF1) mRNA and the phosphorylation of extracellular signalregulated kinase (ERK) and Akt. The data showed that both ß2GPI and reduced ß2GPI inhibited retinal angiogenesis and suppressed the expression of VEGF, VEGFR1, VEGFR2, HIF1, phosphorylated- (p) ERK and pAkt. The effects of reduced ß2GPI were significantly stronger than those of ß2GPI. In conclusion, this study showed that ß2GPI and reduced ß2GPI could inhibit retinal angiogenesis by downregulating the expression of VEGF and its downstream targets. This suggests that ß2GPI and reduced ß2GPI may have potential antiangiogenic activity in vivo.